WO2007143629A1 - Traitement de la neurofibromatose avec des inhibiteurs d'une voie de transduction du signal - Google Patents

Traitement de la neurofibromatose avec des inhibiteurs d'une voie de transduction du signal Download PDF

Info

Publication number
WO2007143629A1
WO2007143629A1 PCT/US2007/070366 US2007070366W WO2007143629A1 WO 2007143629 A1 WO2007143629 A1 WO 2007143629A1 US 2007070366 W US2007070366 W US 2007070366W WO 2007143629 A1 WO2007143629 A1 WO 2007143629A1
Authority
WO
WIPO (PCT)
Prior art keywords
deficient
cells
pi3k
inhibitor
akt
Prior art date
Application number
PCT/US2007/070366
Other languages
English (en)
Inventor
Ruihong Chen
Allan E. Rubenstein
Xiaodong Shen
Jin-Chen Yu
Marco Giovannini
Original Assignee
Nexgenix Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexgenix Pharmaceuticals filed Critical Nexgenix Pharmaceuticals
Publication of WO2007143629A1 publication Critical patent/WO2007143629A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

L'invention concerne des procédés de traitement, prévention ou amélioration de tumeurs ou symptômes provoqués par la neurofibromatose de type 2 (NF2) chez un sujet en administrant à ce dernier une quantité thérapeutiquement efficace d'au moins un inhibiteur de la signalisation de la voie PI3K/AKT ou d'un composé qui inhibe ou ralentit la croissance d'une ou plusieurs tumeurs NF2-déficientes ou des symptômes associés, comparé à l'absence de traitement avec un inhibiteur de la voie PI3K/AKT. L'invention concerne également des procédés d'inhibition de la croissance de tumeurs NF2-déficientes en mettant des cellules tumorales NF2-déficientes en contact avec un inhibiteur ou un composé qui inhibe l'activité d'une ou plusieurs protéines de la voie PI3K/AKT. L'invention concerne en outre des procédés de criblage d'un composé de test destiné au traitement de la NF2 et de conditions apparentées en traitant des cellules NF2-déficientes avec le composé et en évaluant la diminution de l'activité d'une ou plusieurs protéines de la voie PI3K/AKT.
PCT/US2007/070366 2006-06-02 2007-06-04 Traitement de la neurofibromatose avec des inhibiteurs d'une voie de transduction du signal WO2007143629A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81016606P 2006-06-02 2006-06-02
US60/810,166 2006-06-02

Publications (1)

Publication Number Publication Date
WO2007143629A1 true WO2007143629A1 (fr) 2007-12-13

Family

ID=38801828

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/070366 WO2007143629A1 (fr) 2006-06-02 2007-06-04 Traitement de la neurofibromatose avec des inhibiteurs d'une voie de transduction du signal
PCT/US2007/070367 WO2007143630A2 (fr) 2006-06-02 2007-06-04 Traitement de la neurofibromatose avec des inhibiteurs de la hsp90

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/070367 WO2007143630A2 (fr) 2006-06-02 2007-06-04 Traitement de la neurofibromatose avec des inhibiteurs de la hsp90

Country Status (2)

Country Link
CA (1) CA2727100C (fr)
WO (2) WO2007143629A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141738A3 (fr) * 2009-06-03 2011-03-17 President And Fellows Of Harvard College Compositions et procédé pour inhiber la croissance d'une tumeur
WO2016085943A1 (fr) 2014-11-25 2016-06-02 Rastelli, Luca Utilisation d'inhibiteurs du système ubiquitine-protéasome pour le traitement de tumeurs associées à la neurofibromatose de type 2
WO2020053125A1 (fr) * 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement de la neurofibromatose

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150302A1 (fr) * 2007-06-04 2008-12-11 Nexgenix Pharmaceuticals Traitement de la neurofibromatose avec du radicicol et ses dérivés
US8329683B2 (en) 2006-06-02 2012-12-11 Nexgenix Pharmaceuticals, Llc Treatment of neurofibromatosis with radicicol and its derivatives
MX2010007755A (es) * 2008-01-15 2010-12-21 Univ Strasbourg Sintesis de lactonas de acido resorcilico utiles como agentes terapeuticos.
BRPI0906598A2 (pt) 2008-02-01 2015-07-07 Takeda Pharmaceutical Oxim derivattivos como inibidores hsp90
NZ599138A (en) 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080002A1 (en) * 2001-08-13 2005-04-14 Jacks Tyler E. Methods for the treatment and prevention of cancer
US20050203173A1 (en) * 2003-04-03 2005-09-15 Garlich Joseph R. PI-3 kinase inhibitor prodrugs
US20050272755A1 (en) * 2004-06-04 2005-12-08 Pfizer Inc Method for treating abnormal cell growth

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423080A4 (fr) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080002A1 (en) * 2001-08-13 2005-04-14 Jacks Tyler E. Methods for the treatment and prevention of cancer
US20050203173A1 (en) * 2003-04-03 2005-09-15 Garlich Joseph R. PI-3 kinase inhibitor prodrugs
US20050272755A1 (en) * 2004-06-04 2005-12-08 Pfizer Inc Method for treating abnormal cell growth

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HU ET AL.: "Phosphobinositol lipids bind to phosphatidylinositol 3(PI3)-kinase enhancer GTPase and mediate its stimulatory effect on PI3-kinase and Akt signalings", PNAS, vol. 102, no. 46, November 2005 (2005-11-01), pages 16853 - 16858, XP008090825 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141738A3 (fr) * 2009-06-03 2011-03-17 President And Fellows Of Harvard College Compositions et procédé pour inhiber la croissance d'une tumeur
WO2016085943A1 (fr) 2014-11-25 2016-06-02 Rastelli, Luca Utilisation d'inhibiteurs du système ubiquitine-protéasome pour le traitement de tumeurs associées à la neurofibromatose de type 2
US10610563B2 (en) 2014-11-25 2020-04-07 Bioxcel Corporation Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
WO2020053125A1 (fr) * 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement de la neurofibromatose

Also Published As

Publication number Publication date
CA2727100A1 (fr) 2008-12-11
WO2007143630A3 (fr) 2008-03-27
CA2727100C (fr) 2016-04-12
WO2007143630A2 (fr) 2007-12-13

Similar Documents

Publication Publication Date Title
Huang et al. MST4 phosphorylation of ATG4B regulates autophagic activity, tumorigenicity, and radioresistance in glioblastoma
White et al. YAP/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells
Blakely et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer
Fedida-Metula et al. Lipid rafts couple store-operated Ca 2+ entry to constitutive activation of PKB/Akt in a Ca 2+/calmodulin-, Src-and PP2A-mediated pathway and promote melanoma tumor growth
Krygowska et al. PI3K: a crucial piece in the RAS signaling puzzle
WO2007143629A1 (fr) Traitement de la neurofibromatose avec des inhibiteurs d'une voie de transduction du signal
HU229263B1 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
KR20220165809A (ko) 암 치료를 위한 병용 요법
AU2014229985B2 (en) Methods of treating colorectal cancer
US11344601B2 (en) Tumor microenvironment-related target TAK1 and application thereof in inhibition of tumor
WO2009046436A1 (fr) Procédés pour inhiber la sénescence des cellules épithéliales
Zhang et al. Transforming growth factor‐β1 mediates psoriasis‐like lesions via a Smad3‐dependent mechanism in mice
WO2008154470A1 (fr) Inhibiteur de l'activité récepteur du récepteur s1p1 permettant l'inhibition d'une angiogenèse pathologique dans l'œil
Fourneaux et al. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications
US20230035892A1 (en) Methods and compositions for treating cancer
Ki et al. Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors
Carr et al. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination
JP6503289B2 (ja) 脂漏性角化症を治療および予防するための薬剤および方法
US20110245256A1 (en) Use of a pkc inhibitor
Shen et al. AUY922 induces retinal toxicity through attenuating TRPM1
WO2022055893A1 (fr) Combinaison pharmaceutique et traitement antitumoral
Von Achenbach et al. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models
US10457740B1 (en) Methods and compositions for treating cancer using P2RX2 inhibitors
Wang et al. Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer
WO2021170045A1 (fr) Méthodes de traitement de dlbcl à l'aide d'inhibiteurs de btk et de leurs combinaisons

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784313

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 07784313

Country of ref document: EP

Kind code of ref document: A1